In accordance, a recent study of head and neck cancer demonstrated that activation of EGFR and HER2 was correlated with MAPK activation and that ERK1/2 inhibition by cetuximab points to these molecules as potential surrogate markers in the clinical setting (Albanell et al, 2001). Here, ERBB2 is linked to head and neck cancer.